Table 6.
Summary of co-delivery of small molecule drug and siRNA by gold nanomaterials for cancer therapy.
| Delivery System | Small Molecule Drug | siRNA Target | Type of Cancer |
Cell Line | Testing Stage | Ref. |
|---|---|---|---|---|---|---|
| Polyelectrolyte polymers coated gold nanorods (AuNRs) |
Doxorubicin | KRAS | Pancreatic Cancer | Panc-1 |
In vitro
In vivo |
[95] |
| Gold nanoparticles (AuNPs) combined with an engineered bi-functional recombinant fusion protein TRAF(C) (TR) | Doxorubicin | ERBB2 | Ovarian cancer | SK-OV-3, MDA-MB-231, A549, PANC-1, B16F10 |
In vitro
In vivo |
[100] |
| Layer-by-layer assembled gold nanoparticles (LbL-AuNP) | Imatinib mesylate | STAT3 | Melanoma cancer | B16F10 | In vivo | [101] |
Note: KRAS, KRAS proto-oncogene, GTPase; ERBB2, erb-b2 receptor tyrosine kinase 2; STAT3, signal transducer and activator of transcription 3.